Precision Biosciences Inc (NASDAQ: DTIL)’s stock price has gone rise by 9.71 in comparison to its previous close of 5.15, however, the company has experienced a 15.54% increase in its stock price over the last five trading days. benzinga.com reported 2025-02-19 that On Wednesday, Precision BioSciences, Inc. DTIL revealed initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.
Is It Worth Investing in Precision Biosciences Inc (NASDAQ: DTIL) Right Now?
The price-to-earnings ratio for Precision Biosciences Inc (NASDAQ: DTIL) is above average at 110.57x. The 36-month beta value for DTIL is also noteworthy at 1.62. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DTIL is 3.67M, and at present, short sellers hold a 20.62% of that float. The average trading volume of DTIL on February 20, 2025 was 491.57K shares.
DTIL’s Market Performance
DTIL stock saw an increase of 15.54% in the past week, with a monthly gain of 13.91% and a quarterly increase of -26.62%. The volatility ratio for the week is 7.25%, and the volatility levels for the last 30 days are 7.43% for Precision Biosciences Inc (DTIL). The simple moving average for the past 20 days is 12.63% for DTIL’s stock, with a -33.70% simple moving average for the past 200 days.
Analysts’ Opinion of DTIL
Many brokerage firms have already submitted their reports for DTIL stocks, with BMO Capital Markets repeating the rating for DTIL by listing it as a “Outperform.” The predicted price for DTIL in the upcoming period, according to BMO Capital Markets is $34 based on the research report published on January 10, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see DTIL reach a price target of $19. The rating they have provided for DTIL stocks is “Buy” according to the report published on April 30th, 2024.
BMO Capital Markets gave a rating of “Outperform” to DTIL, setting the target price at $7 in the report published on June 17th of the previous year.
DTIL Trading at 12.97% from the 50-Day Moving Average
After a stumble in the market that brought DTIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.92% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 7.25%, as shares surge +23.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.58% lower at present.
During the last 5 trading sessions, DTIL rose by +15.54%, which changed the moving average for the period of 200-days by -46.09% in comparison to the 20-day moving average, which settled at $5.02. In addition, Precision Biosciences Inc saw 48.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DTIL starting from List Alan, who proposed sale 672 shares at the price of $5.04 back on Jan 24 ’25. After this action, List Alan now owns shares of Precision Biosciences Inc, valued at $3,387 using the latest closing price.
Scimeca Dario, the General Counsel and Secretary of Precision Biosciences Inc, sale 8,928 shares at $4.79 during a trade that took place back on Jan 22 ’25, which means that Scimeca Dario is holding 24,353 shares at $42,765 based on the most recent closing price.
Stock Fundamentals for DTIL
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.93 for the gross margin
The net margin for Precision Biosciences Inc stands at 0.11. The total capital return value is set at -0.11. Equity return is now at value 24.44, with 7.23 for asset returns.
Based on Precision Biosciences Inc (DTIL), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -1.59. The debt to equity ratio resting at 0.47. The interest coverage ratio of the stock is -8.23.
Currently, EBITDA for the company is -32.04 million with net debt to EBITDA at -3.64. When we switch over and look at the enterprise to sales, we see a ratio of -0.32. The receivables turnover for the company is 48.54for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.22.
Conclusion
In summary, Precision Biosciences Inc (DTIL) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
